Vascular calcification—a matter of damage limitation?

with predialysis renal failure? Circulation 2000; 102: 871–875 36. Bayés B, Cruz Pastor M, Bonal J et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106–112 37. van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106–112 38. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18: 282–289 39. Dierkes J, Domrose U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 1999; 51: 108–115 40. van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Carotid artery stiffness in patients with endstage renal disease: no effect of long-term homocysteinelowering therapy. Clin Nephrol 2000; 53: 33–41 41. Ingrosso D, Cimmioni A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361: 1693–1699 42. van Guldener C, Stam F, Stehouwer CD. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation. Clin Chem Lab Med 2005; 43: 1026–1031 43. Jamison RL, Hartigan P, Gaziano JM et al. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials 2004; 1: 451–460